The Michael J Fox Foundation awards one million dollars to Montara Therapeutics to test a brain specific therapy for Parkinson's

A San Francisco biotechnology company called Montara Therapeutics has secured a funding boost of approximately one million dollars from The Michael J Fox Foundation for Parkinson's Research. This grant aims to advance a unique therapeutic program that focuses on clearing the harmful protein accumulation inside the brain that is a hallmark of the condition. The research targets a specific protein called mTOR which effectively acts as a brake on the natural recycling system of the body. When this brake is active cells cannot easily clear out waste. By inhibiting mTOR scientists can lift that brake and trigger autophagy which is the internal cellular housekeeping process that breaks down and removes toxic components. For people with Parkinson's turning this system on could help clear away alpha synuclein clusters which are the toxic protein clumps that damage brain cells over time. While drugs that block mTOR have shown great promise in laboratory models they have historically failed as neurological therapies because the protein performs critical jobs throughout the entire body. Blocking it everywhere leads to severe systemic complications including a weakened immune system and metabolic disruption. To overcome this major hurdle Montara Therapeutics is utilising its specialized BrainOnly platform. The strategy pairs an brain penetrating therapeutic with a custom peripheral blocker designed to stop the medication from working anywhere outside the central nervous system. This ensures that the drug only unlocks the cellular cleaning process within the brain while leaving the rest of the body completely unaffected. With this new financial backing researchers will evaluate several existing mTOR inhibitors in combination with their peripheral blocker. The team will test these variations in cellular and animal models to find the most effective and safe combinations capable of reducing alpha synuclein buildup. If successful the project could pave the way for a brand new class of therapies designed to alter the progression of Parkinson's rather than just managing the day to day symptoms.